CD8A and cancer: Regarding clinical evidence of synergy, studies in mouse cancer models have demonstrated that the compound D18, when combined with different ICIs, significantly promotes T cell activation and expansion by activating the TLR7/8 signaling pathway, ultimately increasing the overall infiltration of activated CD8+ T cells in tumor tissue (196, 197).